Rheumatology treats musculoskeletal and autoimmune diseases, including arthritis, lupus, gout, and vasculitis.
Send us all your questions or requests, and our expert team will assist you.
Systemic sclerosis, also known as scleroderma, is one of the most complex and difficult autoimmune diseases to manage. It stands out from other connective tissue disorders because it involves three main problems: widespread blood vessel damage, problems with the immune system, and uncontrolled scarring of tissues. Unlike conditions that affect just one joint or organ, scleroderma affects the whole body and changes its structure at the cellular level. Today, experts see it not just as a skin-hardening disease but as a breakdown in the body’s normal repair process. Normally, when tissue is injured, the body repairs it and then stops. In scleroderma, this repair process stays switched on, causing too much collagen and other materials to build up, which harms the skin and internal organs.
Classifying scleroderma is important for predicting how the disease will progress and choosing the right treatment. Doctors divide scleroderma into localized types, like morphea and linear scleroderma, which mainly affect the skin, and systemic types, which also involve internal organs. Systemic sclerosis is split into limited and diffuse forms, depending on how much skin is affected. The limited form usually causes slow skin thickening on the hands, feet, and face. The diffuse form causes faster and more widespread skin thickening, including the trunk and upper arms and legs, and it carries a higher risk of early and serious problems with the lungs, kidneys, and heart.
Recent studies suggest that the blood vessels are the first part of the body affected in scleroderma. The problem starts in the endothelium, which is the thin layer of cells lining the blood vessels. In people who are genetically at risk, something in the environment, a virus, or a chemical may damage these cells. This damage sets off a chain reaction, causing the cells to die and small blood vessels to be lost. This loss of tiny blood vessels, called microvascular rarefaction, leads to long-term low oxygen levels in tissues.
Normally, when tissues lack oxygen, the body makes substances that help grow new blood vessels to fix the problem. In scleroderma, this repair process does not work properly. The body does not make enough new cells to replace damaged blood vessels, and the existing vessels change in ways that make things worse. The inner layer of small arteries thickens, narrowing the space for blood to flow. This blood vessel problem causes many of the symptoms of scleroderma, from color changes in the fingers (Raynaud’s phenomenon) to serious kidney issues. New treatments in regenerative medicine are being developed to help repair blood vessels and improve blood flow.
The immune system has two main roles in scleroderma: it causes damage and also leads to scarring. After the blood vessels are hurt, the immune system overreacts. Certain immune cells, called T cells and B cells, move into the area around the blood vessels and release chemicals that cause inflammation and produce autoantibodies. These chemicals do more than just cause swelling; they target fibroblasts, which are cells that help build and repair tissues. Signals from the immune system cause these fibroblasts to become myofibroblasts, which are more active and produce more scar tissue.
Myofibroblasts are cells that make a lot of collagen, which is needed to heal wounds. In scleroderma, these cells do not turn off and keep making too much collagen, which forms stiff, disorganized scar tissue. This scarring replaces normal tissue and causes the skin to tighten and lose its stretchiness. If this happens in the lungs or heart, those organs become stiff and cannot work properly. Stopping this process is a main goal of treatment. Doctors use medicines to calm the immune system and are also developing new therapies to help these cells stop making scar tissue and start repairing tissue in a healthier way.
Scleroderma is considered a rare disease, yet its impact on individual health and healthcare systems is profound due to its chronicity and complexity. Epidemiological studies reveal a global distribution, though prevalence rates vary by geography and ethnicity, suggesting a complex interplay between genetic ancestry and environment. Scleroderma is rare, but it has a big impact on people’s health and on healthcare systems because it is long-lasting and complicated. It occurs worldwide, but how common it is depends on where people live and their ethnic background, which suggests both genes and environment play a role. The disease affects women much more often than men, especially during and after their childbearing years. In some groups, women are affected four times as often as men. This difference has led scientists to study whether hormones or the presence of fetal cells in women’s blood might help explain why women are more likely to develop autoimmune diseases like scleroderma. In a Mendelian fashion, there is a familial clustering of autoimmune diseases. Individuals with a family history of lupus, rheumatoid arthritis, or thyroid disease may have a slightly elevated risk, reinforcing the concept that these conditions share common genetic pathways related to immune tolerance and regulation.
Treatment for scleroderma is changing, moving from just managing symptoms to actually trying to change the course of the disease and repair tissues. New approaches like using a patient’s own stem cells or regenerative cells from fat are leading this change. These treatments are based on the idea that the immune system can be reset and that damaged tissues can heal if the environment in the body is improved.
Stem cells, particularly mesenchymal stem cells derived from bone marrow or fat tissue, possess unique immunomodulatory properties. They can inhibit the proliferation of autoreactive T cells and suppress excessive B-cell activity. Furthermore, they secrete soluble factors that are antifibrotic and angiogenic, directly countering the two main pathological drivers of the disease. By integrating these advanced biological therapies with established pharmacological protocols, centers of excellence are moving towards a holistic model of care that addresses the root causes of systemic sclerosis rather than just its downstream effects.
Send us all your questions or requests, and our expert team will assist you.
The primary distinction lies in the extent of skin involvement and the rate of disease progression. The limited form involves skin thickening confined to the face, hands, and feet, and generally progresses slowly over many years. The diffuse form involves rapid skin thickening that spreads to the trunk and upper arms and is associated with a much higher risk of early internal organ damage.
Fibrosis is the excessive accumulation of collagen, which turns soft, functional tissue into hard scar tissue. When this occurs in internal organs like the lungs or gastrointestinal tract, it stiffens the tissue, preventing normal movement and function. For example, lung fibrosis prevents the air sacs from fully expanding, leading to difficulty breathing.
Research suggests that the very first injury in scleroderma occurs in the lining of the small blood vessels. This endothelial damage triggers an immune response, which eventually leads to scarring. Symptoms like Raynaud’s phenomenon, in which blood vessels spasm and constrict, often appear years before any skin changes, confirming the early vascular origin.
Scleroderma is not directly inherited like eye color or height, and most patients do not have a parent with the disease. However, susceptibility genes can be passed down. It is common to find that family members of patients have other autoimmune conditions, suggesting a shared genetic predisposition to immune system dysregulation.
Myofibroblasts are the cells responsible for producing collagen and scar tissue. In a healthy body, they are only active during wound healing. In scleroderma, they become permanently overactive due to faulty immune signals, continuously producing collagen that accumulates, thickens, and hardens tissues.
Your Comparison List (you must select at least 2 packages)
